Sanofi and GSK have formed an agreement with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine.   The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein technology used by Sanofi to produce an influenza vaccine, and GSK’s established pandemic adjuvant technology.   Collaborating with the U.S. Department of Health and Human Services (HHS) and Department of Defense will help fund the ...